WO1998001558A3 - Protein and peptide vaccines for inducing mucosal immunity - Google Patents
Protein and peptide vaccines for inducing mucosal immunity Download PDFInfo
- Publication number
- WO1998001558A3 WO1998001558A3 PCT/US1997/012253 US9712253W WO9801558A3 WO 1998001558 A3 WO1998001558 A3 WO 1998001558A3 US 9712253 W US9712253 W US 9712253W WO 9801558 A3 WO9801558 A3 WO 9801558A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- protein
- transmitted diseases
- mucosal immunity
- peptide vaccines
- inducing mucosal
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/085—Staphylococcus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/002—Protozoa antigens
- A61K39/005—Trypanosoma antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/002—Protozoa antigens
- A61K39/008—Leishmania antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/002—Protozoa antigens
- A61K39/015—Hemosporidia antigens, e.g. Plasmodium antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/21—Retroviridae, e.g. equine infectious anemia virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6018—Lipids, e.g. in lipopeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6068—Other bacterial proteins, e.g. OMP
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
- C12N2740/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Immunology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Abstract
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP50537298A JP2001505535A (en) | 1996-07-10 | 1997-07-10 | Protein and peptide vaccines for inducing mucosal immunity |
AU36629/97A AU739723B2 (en) | 1996-07-10 | 1997-07-10 | Protein and peptide vaccines for inducing mucosal immunity |
EP97933443A EP0929678A2 (en) | 1996-07-10 | 1997-07-10 | Protein and peptide vaccines for inducing mucosal immunity |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US2168796P | 1996-07-10 | 1996-07-10 | |
US60/021,687 | 1996-07-10 |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09214701 A-371-Of-International | 1999-09-30 | ||
US09/938,406 Division US20020155120A1 (en) | 1996-07-10 | 2001-08-21 | Protein and peptide vaccines for inducing mucosal immunity |
Publications (2)
Publication Number | Publication Date |
---|---|
WO1998001558A2 WO1998001558A2 (en) | 1998-01-15 |
WO1998001558A3 true WO1998001558A3 (en) | 1998-05-14 |
Family
ID=21805590
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1997/012253 WO1998001558A2 (en) | 1996-07-10 | 1997-07-10 | Protein and peptide vaccines for inducing mucosal immunity |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP0929678A2 (en) |
JP (1) | JP2001505535A (en) |
AU (1) | AU739723B2 (en) |
CA (1) | CA2259961A1 (en) |
WO (1) | WO1998001558A2 (en) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5961970A (en) | 1993-10-29 | 1999-10-05 | Pharmos Corporation | Submicron emulsions as vaccine adjuvants |
DE60121136T2 (en) | 2000-02-15 | 2007-06-06 | Id Biomedical Corporation Of Quebec, Ville St. Laurent | Proteasome-INFLUENZA VIRUS VACCINE COMPOSITION |
EP1721618A3 (en) * | 2000-02-15 | 2007-01-10 | ID Biomedical Corporation of Quebec | Proteosome influenza vaccine composition |
EP2198882A3 (en) * | 2001-01-12 | 2010-10-13 | Novartis Vaccines and Diagnostics, Inc. | Nucleic acid mucosal immunization |
MXPA03008154A (en) * | 2001-03-09 | 2004-11-12 | Id Biomedical Corp Quebec | A novel proteosome-liposaccharide vaccine adjuvant. |
US7255867B2 (en) | 2002-11-15 | 2007-08-14 | Id Biomedical Corporation Of Quebec | Vaccine |
GB201520568D0 (en) | 2015-11-23 | 2016-01-06 | Immunocore Ltd | Peptides |
GB201520550D0 (en) | 2015-11-23 | 2016-01-06 | Immunocore Ltd & Adaptimmune Ltd | Peptides |
GB201520595D0 (en) * | 2015-11-23 | 2016-01-06 | Immunocore Ltd & Adaptimmune Ltd | Peptides |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1995011700A1 (en) * | 1993-10-29 | 1995-05-04 | Pharmos Corp. | Submicron emulsions as vaccine adjuvants |
-
1997
- 1997-07-10 WO PCT/US1997/012253 patent/WO1998001558A2/en active Application Filing
- 1997-07-10 JP JP50537298A patent/JP2001505535A/en not_active Ceased
- 1997-07-10 AU AU36629/97A patent/AU739723B2/en not_active Ceased
- 1997-07-10 CA CA002259961A patent/CA2259961A1/en not_active Abandoned
- 1997-07-10 EP EP97933443A patent/EP0929678A2/en not_active Ceased
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1995011700A1 (en) * | 1993-10-29 | 1995-05-04 | Pharmos Corp. | Submicron emulsions as vaccine adjuvants |
Non-Patent Citations (11)
Also Published As
Publication number | Publication date |
---|---|
AU739723B2 (en) | 2001-10-18 |
AU3662997A (en) | 1998-02-02 |
CA2259961A1 (en) | 1998-01-15 |
EP0929678A2 (en) | 1999-07-21 |
WO1998001558A2 (en) | 1998-01-15 |
JP2001505535A (en) | 2001-04-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Hu et al. | Immunostimulating complexes (ISCOMs) for nasal vaccination | |
Morein et al. | Current status and potential application of ISCOMs in veterinary medicine | |
Kurar et al. | Nucleic acid vaccination of Brucella abortus ribosomal L7L12 gene elicits immune response | |
AU2015265884B2 (en) | Vaccine composition against Streptococcus suis infection | |
GB8610983D0 (en) | Enhancement of antigen immunogenicity | |
ES2141750T5 (en) | COMPOSITION THAT CONTAINS AT A TIME A SOLUBLE FORM AND AN INSOLUBLE FORM OF AN IMMUNOGEN. | |
PL392964A1 (en) | Hyperimmune serum reactive antigen, the use of this antigen for the production of a pharmaceutical formulation, fragment of the hiperimmune antigen, antigen auxiliary epitopes, a vaccine containing the hyperimmune serum reactive antigen, formulation containing antibodies, process for the preparation of this formulation, the use of the formulation for the treatment of staphylococcal infections, and screening method | |
RU2000116260A (en) | LTB ADJUVANT VACCINES | |
Nyika et al. | DNA vaccination with map1 gene followed by protein boost augments protection against challenge with Cowdria ruminantium, the agent of heartwater | |
WO1998001558A3 (en) | Protein and peptide vaccines for inducing mucosal immunity | |
WO2001079259A8 (en) | Javelinization of protein antigens to heat shock proteins | |
Hinkula et al. | Nucleic acid vaccination with HIV regulatory genes: a combination of HIV-1 genes in separate plasmids induces strong immune responses | |
McCLUSKIE et al. | Immunization against hepatitis B virus by mucosal administration of antigen–antibody complexes | |
WO2001060404A3 (en) | Use of opri lipoprotein from pseudomonas as a th1 inducing natural adjuvant for heterologous antigens | |
MX9801089A (en) | Hybrid protein comprising t-helper cell stimulating epitopes and b-cell epitopes from the major outer membrane protein of chlamydia trachomatis and its use as a vaccine. | |
Morein | Iscoms | |
Toussaint et al. | Prime-boost strategies combining DNA and inactivated vaccines confer high immunity and protection in cattle against bovine herpesvirus-1 | |
Wang et al. | Immunogenicity of a bovine viral diarrhea virus E2–C3d fusion protein containing a bovine homolog of C3d | |
EP1490100B1 (en) | Combined dna/protein vaccine compositions | |
EA200200931A1 (en) | SYSTEM FOR DELIVERY OF THE VACCINE THROUGH THE MUDDY SHELL OF URINARY OR ANORECTAL TRACT | |
WO2005021574A3 (en) | Induction of antiviral neutralizing antibodies in humans and animals | |
CA2133108A1 (en) | Pasteurella haemolytica type a-1 bacterin-toxoid vaccine | |
NZ528055A (en) | Immunogenic liposome compositions comprising vesicle forming lipids and an antigenic construct and methods of inducing an immune response using them | |
AU2667600A (en) | Identification of specific differentially expressed antigens | |
O’Donovan et al. | A vector expressing feline mature IL-18 fused to IL-1β antagonist protein signal sequence is an effective adjuvant to a DNA vaccine for feline leukaemia virus |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AL AM AT AU AZ BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE HU IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TR TT UA UG US UZ VN AM AZ BY KG KZ MD RU TJ TM |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH KE LS MW SD SZ UG ZW AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
AK | Designated states |
Kind code of ref document: A3 Designated state(s): AL AM AT AU AZ BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE HU IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TR TT UA UG US UZ VN AM AZ BY KG KZ MD RU TJ TM |
|
AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): GH KE LS MW SD SZ UG ZW AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF |
|
ENP | Entry into the national phase |
Ref document number: 2259961 Country of ref document: CA Ref country code: CA Ref document number: 2259961 Kind code of ref document: A Format of ref document f/p: F |
|
ENP | Entry into the national phase |
Ref country code: JP Ref document number: 1998 505372 Kind code of ref document: A Format of ref document f/p: F |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1997933443 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWP | Wipo information: published in national office |
Ref document number: 1997933443 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 09214701 Country of ref document: US |
|
ENPW | Started to enter national phase and was withdrawn or failed for other reasons |
Ref document number: PI9711099 Country of ref document: BR Kind code of ref document: A2 Free format text: PEDIDO CONSIDERADO RETIRADO EM RELACAO AO BRASIL E ARQUIVADO POR NAO ATENDER O DISPOSTO NOS ITENS 9.2 E 9.2.1 DO ATO NORMATIVO NO 128/1997 DE 05/03/1997 E POR NAO TER CUMPRIDO EXIGENCIA PUBLICADA NA RPI NO 1873 DE 28/11/2006. |